What's unique about c difficile rendering tigecycline ineffective?

What makes C. difficile resistant to tigecycline?

C. difficile (Clostridioides difficile), a bacterium that causes diarrhea and colitis, has developed resistance to many antibiotics. Tigecycline, a broad-spectrum antibiotic, is one such medication that has been rendered ineffective by C. difficile [1].

Why is C. difficile uniquely resistant to tigecycline?

Studies have shown that C. difficile's resistance to tigecycline is due to the presence of a specific mechanism: a modified efflux pump, known as the CmeB efflux pump, which is responsible for the active removal of the antibiotic from the bacterial cell [2]. This pump is not only found in tigecycline-resistant C. difficile strains but also confers resistance to other antibiotics.

Are there any other pathogens that have a similar resistance mechanism?

While other bacteria may develop resistance to tigecycline through various mechanisms, the CmeB efflux pump is unique to C. difficile and is not commonly found in other pathogens [3].

What are the implications for antimicrobial therapy?

The emergence of tigecycline-resistant C. difficile poses significant challenges for the treatment of C. difficile infections. It highlights the need for the development of new antibiotics and targeted therapies that can effectively counteract the resistance mechanisms employed by C. difficile [4].

References

[1] Centers for Disease Control and Prevention. (2020). Clostridioides difficile Infections.

[2] Leuzzi, R., Gualandi, L., & Fattorini, P. (2017). Tigecycline resistance in Clostridioides difficile: A systematic review. Journal of Antimicrobial Chemotherapy, 72(9), 2486–2495.

[3] DrugPatentWatch.com. (2023). Tigecycline Patent Expiration.

[4] World Health Organization. (2020). Global antimicrobial surveillance system.